Stay updated with breaking news from Matthew During. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zacks Investment Research cut shares of Ovid Therapeutics (NASDAQ:OVID – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Saturday, Zacks.com reports. According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product […]
Ovid Therapeutics (NASDAQ:OVID – Get Rating) released its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.22), MarketWatch Earnings reports. NASDAQ:OVID opened at $3.13 on Wednesday. The firm has a market cap of $213.13 million, a PE ratio of 1.75 and […]
Equities research analysts forecast that Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) will announce earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings. Ovid Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which suggests a positive […]
Novavax, Inc Novavax, Inc. is a clinical-stage vaccine company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. With the onset of the global pandemic last year, the company has also ventured into making COVID-19 vaccines. Despite not having any product in the market yet and facing delays in production, it is still expected to be one of the leading vaccine candidates. The company’s vaccine has proven to be just as potent as other vaccine frontrunners. On Tuesday, President Joe Biden hinted that Novavax’s vaccine may be ne...
Press release content from Business Wire. The AP news staff was not involved in its creation. Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics April 26, 2021 GMT BROOKLYN, N.Y.--(BUSINESS WIRE)--Apr 26, 2021-- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company’s Scientific Advisory Board, effective April 26, 2021. Dr. ...